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Abstract
Meta-analytic methods may be used to combine evidence from different sources
of information. Quite commonly, the normal-normal hierarchical model (NNHM)
including a random-effect to account for between-study heterogeneity is utilized for
such analyses. The same modeling framework may also be used to not only derive
a combined estimate, but also to borrow strength for a particular study from another
by deriving a shrinkage estimate. For instance, a small-scale randomized controlled
trial could be supported by a non-randomized study, e.g. a clinical registry. This
would be particularly attractive in the context of rare diseases. We demonstrate
that a meta-analysis still makes sense in this extreme case, effectively based on a
synthesis of only two studies, as illustrated using a recent trial and a clinical registry
in Creutzfeld-Jakob disease. Derivation of a shrinkage estimate within a Bayesian
random-effects meta-analysis may substantially improve a given estimate even based
on only a single additional estimate while accounting for potential effect heterogeneity
between the studies. Alternatively, inference may equivalently be motivated via a
model specification that does not require a common overall mean parameter but
considers the treatment effect in one study, and the difference in effects between the
studies. The proposed approach is quite generally applicable to combine different
types of evidence originating e.g. from meta-analyses or individual studies. An
application of this more general setup is provided in immunosuppression following
liver transplantation in children.
Keywords
Random-effects meta-analysis; Bayesian statistics; Between-study heterogeneity;
Shrinkage estimation; Posterior predictive p-values
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Introduction
In clinical research of orphan diseases, one of the major problems is often the recruitment
of a sufficient number of subjects to perform a meaningful clinical trial. Examples
include neuromyelitis optica1, myocarditis2, and Creutzfeld-Jakob disease (CJD)3. In
such cases, it may be possible to gain some power by using more sophisticated trial
designs, and it is often desirable to be able to formally utilize additional information
external to the actual trial, which may be implemented via the use of informative prior
distributions in the eventual analysis4. The external information could be in the form
of related studies or elicited expert opinion5. For instance, in the context of a small-
scale randomized controlled trial in idiopathic nephrotic syndrome in children, a rare
condition, Thall et al.6 recently proposed the elicitation of expert opinions on response
probabilities based on the bins-and-chips approach7.
When considering external evidence, the obvious danger is that a too simplistic
approach may lead to a “naı¨ve” pooling of initially separate data. For example, while
data from non-randomized studies (e.g. clinical registries) may undoubtedly contribute
complementing information to a randomized clinical trial, one may want to prevent a
complete mixing of both types of data, which would in a sense also invalidate the original
randomization. Rather it seems desirable to stratify the analysis for the different sources
by explicitly allowing for potential heterogeneity between data sets, which then implicitly
downweights the impact on one another. Here the weights depend on the observed
similarity of estimates, also known as dynamic borrowing of information8. The eventual
analysis then may refer explicitly to the outcome of the randomized trial, and not to
some overall average, as generally more weight is placed on evidence from randomized
controlled trials.
A simple approach originally proposed by Pocock9 was recently implemented by
Schoenfeld et al.10, who investigated the use of adult data to support the analysis of a
paediatric trial, and who utilized a variance component of known (elicited) magnitude to
account for heterogeneity between the two studies’ estimates. A closely related approach
is implemented in the normal-normal hierarchical model (NNHM) that is commonly
utilized in random-effects meta-analysis; the difference essentially is that heterogeneity
is treated as an unknown for which a prior distribution may be specified. Technically,
inference on the study of primary interest is done by investigating the corresponding
shrinkage estimate. The contribution of information from additional studies then may
readily be evaluated by considering the corresponding meta-analytic-predictive (MAP)
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prior11,12. The NNHM is readily generalized (and in fact most commonly used) for
combining more than two studies; such an approach may e.g. be used to extrapolate
information from early-phase studies in the approval process12. In the case of two studies,
the NNHM can also be shown to be to some extent equivalent to a similar, more general
model specification as we will explain below.
While the interpretation of parameters within the familiar NNHM context is
straightforward and with the inclusion of an unknown heterogeneity parameter it is
intended that evidence from separate studies is sufficiently loosely connected to provide
a robust estimation framework, it is not obvious to what extent this approach actually
improves estimates in the extreme case of only two studies or more generally two data
sources. Here we develop a suitable statistical hierarchical model to include two sources
of data, e.g., two studies or meta-analyses. Within the proposed model we describe
a shrinkage estimator and inference methods including posterior predictive p-values.
Furthermore, the value of this approach in the particular case of only two studies is
evaluated in simulations.
The manuscript is organized as follows. In the next section we present the statistical
model and, in particular, shrinkage estimation and inference. The following sections are
dedicated to a simulation study investigating the operating characteristics of the proposed
methodology and an application in CJD. Motivated by a meta-analysis investigating the
effect of immunosuppression in paediatric liver transplantation patients, we extend the
shrinkage applications to more general settings considering two data sources, e.g. two
meta-analyses, rather than two studies. Finally, we close with some conclusions and a
brief discussion.
Statistical model and shrinkage estimation
The normal-normal hierarchical model
The most commonly used model for random-effects meta-analysis is the normal-normal
hierarchical model (NNHM). This model is applicable for the joint analysis of several
(k) real-valued effect measurements yi that have individual standard errors σi associated
(i = 1, . . . , k). Here it is assumed that each observation yi is a noisy measurement of
an underlying true value θi with a normally distributed offset whose magnitude is given
through the (known) standard error σi:
yi|θi ∼ N(θi, σ2i ). (1)
The θi then may be more or less similar across measurements; at the study level, a certain
amount of heterogeneity is anticipated by introducing another variance component τ and
assuming
θi|µ, σ ∼ N(µ, τ2) (2)
where the overall effect µ and heterogeneity τ ≥ 0 are unknown. If τ = 0, the model
simplifies to the fixed-effect model, in which θ1 = · · · = θk = µ, but in general this is
a random-effects model13–15. In the following, we will mostly be concerned with the
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special case of analyzing only k = 2 studies. Note that while classically, in the meta-
analysis context, the yi usually originate from different studies, more generally these
may also be estimates of other kinds, e.g., estimates from meta-analyses.
Shrinkage estimation
Quite commonly, the main interest lies in determining the overall effect µ. When the aim
of the analysis is to provide a basis for planning a new study, it may also be of interest
to predict a future outcome θk+1. In some cases, however, it is of interest to derive an
updated estimate for a particular (ith) study effect θi, which is informed by the remaining
studies under consideration.
If the heterogeneity τ was zero, then the model would reduce to the fixed-effect
model, and all estimates yi would effectively relate to the same parameter (θi = µ),
which may then be jointly estimated by simply averaging the estimates yi (with “inverse
variance” weights). If the heterogeneity appears to be close to zero, then the model will
behave similarly to the fixed-effect model, and all estimated study effects θi will be
“shrunk” towards the estimated overall mean µ to some degree. If on the other hand
the heterogeneity is large, then there is very little to be learned from one estimate (yi)
about another parameter (θj , j 6= i), and different estimates only provide very little
support to one another. Effectively, this results in more or less shrinkage towards the
overall mean µ, depending on the apparent heterogeneity in the data12,16. This shrinkage
estimation of study-specific means θi, which is also known as best linear unbiased
prediction (BLUP) in a frequentist framework17–19, will be our focus in the following.
When the heterogeneity τ is assumed fixed and known (and an improper uniform prior
for µ is used), then the frequentist and Bayesian approaches lead to identical mean effect
(µ)20 as well as shrinkage (θi) estimates
17,21; in general, however, these are different.
The Bayesian approach to meta-analysis
The inference problems within the NNHM may be approached using frequentist or
Bayesian methods13–15,21,22. A Bayesian approach has proven especially useful in cases
where large-sample asymptotics do not apply23, e.g., for the analysis of few studies20 or
even only two studies24. Here, we will follow a Bayesian approach and investigate its
properties in some more detail.
Within the NNHM we have several unknowns; firstly the study-specific effects θi,
whose hyperprior is given through (2). For the overall mean effect µ it is often convenient
to use a non-informative (improper) uniform prior. The heterogeneity τ ≥ 0 determines
the expected variability between individual studies; depending on the measurement scale
of the considered effects, in practical applications a plausible upper bound can usually be
specified. Half-normal (HN) priors (e.g. with scale parameters 0.5 or 1.0) have proven
useful for example in the context of logarithmic odds-ratio (log-OR) endpoints20,22,25. An
analogous reasoning similarly applies for many log-transformed endpoints, like relative
risks or hazard ratios; if different studies are considered unlikely to differ by more than
a certain factor, then one can usually translate this into a prior specification for the
heterogeneity τ on the logarithmic scale21,22.
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The heterogeneity τ is usually considered a nuisance parameter, while the primary
interest is in inferring the overall effect (µ), a prediction (θk+1), or a shrinkage
estimate (θi). Within the Bayesian framework, shrinkage estimation may be motivated
in two different ways; the meta-analytic-combined (MAC) approach simply considers
the shrinkage estimate as one of the parameters in the NNHMmodel, where all k studies
are analyzed jointly. The meta-analytic-predictive (MAP) approach on the other hand
considers the same problem sequentially: first, all but the ith study are analyzed, and
the derived posterior (predictive) distribution then constitutes the prior for the analysis
of the ith study. Both approaches can be shown to be equivalent and lead to identical
results11, but the MAP approach allows to explicate the information ‘borrowed’ from the
additional estimates via the MAP prior. Technically, inference requires integration over
the parameters’ posterior distribution16,22, e.g. to derive the relevant marginal posterior
distribution for shrinkage estimation (p(θi|y1, y2, σ1, σ2)). Computations for inference
within the NNHM may be performed in R using the bayesmeta package21,26. In the
following, the shown estimates will be posterior medians, and credible intervals are
determined as shortest posterior intervals.
Posterior predictive p-values
Posterior predictive p-values are conceptually closely related to “classical” p-values, and
were originally developed in the context of model checking16,27,28. The definition is
relatively straightforward; like a classical p-value, it is based on a null hypothesis H0
and a pre-specified (“test-”) statistic or “discrepancy variable” T (·), which is a function
of the data. The statistic T is (as usual) defined so that it is sensitive to deviations
from the null hypothesis. The realised statistic value T (y) then is determined for the
present data set y. In order to judge whether the statistic value is “sufficiently extreme”
to constitute evidence against the null hypothesis, it is compared against its posterior
predictive distribution, conditional onH0.
Similarly to the usual p-values, this means a comparison against values of the statistic
amongst data sets that might have occurred conditioning on the observed data as well as
the null hypothesis. Technically, posterior predictive p-values are often easily computed
using Monte Carlo sampling, which here means first drawing parameter values from the
intersection of the parameters’ posterior distribution and null hypothesis, then drawing a
data set y⋆ from the corresponding predictive distribution, and determining the statistic
value T (y⋆). Repeated sampling then allows to explore the relevant distribution of
statistic values and eventually compute p-values via the corresponding tail probabilities.
While posterior predictive p-values generally do not follow a uniform distribution under
the null hypothesis, the deviation is usually on the conservative side27,29.
The test statistic to be used needs to be pre-specified. For instance, an obvious choice
for the overall effect µ may be the posterior probability of a non-beneficial effect, i.e.,
T (y) = P(µ > 0 | y). (3)
The null hypothesis then is usually specified for a certain parameter as one- or two-sided.
Accordingly, the test statistic’s relevant distribution (or the sampling scheme, in case of
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MCMC computation), as well as the statistic’s rejection region are affected. Computation
of posterior predictive p-values is also implemented in the bayesmeta R package21.
The reference model as an alternative variation of the NNHM
When meta-analyzing a pair of estimates, the common NNHM may sometimes be hard
to motivate, as an exchangeable model of both estimates θi centered around a common
mean value µ may seem inappropriate. Consider for example the joint analysis of
randomized and observational data; reference to a commonmean parameterµ or identical
variances τ2 may be counterintuitive in such a case. An “asymmetric” treatment of both
estimates in terms of a “reference” estimate and a “secondary”, related observable with
an uncertain amount of offset associated may seem more appealing. It is possible to
formulate a slight variation of the NNHM following this second approach, which may
seem more realistic, and for which one can then show that both approaches are equivalent
as far as shrinkage estimates are concerned. In the following, we will refer to this model
variation as the reference model.
Suppose that the prior for the effect µ in the NNHM is given by an (improper) uniform
distribution, and that the heterogeneity prior is defined through a density p⋆(τ). Then the
model variation is defined as follows; for the observables yi we assume
yi|ϑi ∼ N(ϑi, σ2i ), (4)
which so far is analogous to the NNHM setup. At the next hierarchy level, we then specify
ϑ1|α, β ∼ N(α, 0) (i.e., ϑ1 = α), (5)
ϑ2|α, β ∼ N(α, β2). (6)
where the “effect” parameter α again has an improper uniform prior and the variance
component β now has a prior density given by 1√
2
p⋆
(
β√
2
)
. The parameter β hence has
a prior that is scaled by a factor of
√
2 relative to τ , which corresponds to a factor 2
difference for the squared parameters (the variances).
The reference model parametrisation of the problem is different here in that the two
observables yi are treated asymmetrically. The first one (y1) measures the parameter α
(the reference) “directly”, while the second one (y2) includes an additional offset with
variance β2. The variance component β again implements the heterogeneity between
first and second observable, but in a slightly different manner than in the original NNHM.
While the parameterizations are different, the associated shrinkage estimates (for θi or
ϑi) are identical, as is shown in detail in the Appendix. Since ϑ1 = α, the shrinkage
estimate for ϑ1 is identical to an estimate ofα in this context. The NNHM’s heterogeneity
(τ ) prior needs to be re-scaled by a factor of
√
2 to yield the corresponding β prior.
Note, however, that the equivalence only holds for the case of k = 2 estimates, and an
(improper) uniform effect prior; for other cases, the model would need to be adapted
accordingly.
As has been pointed out by Neuenschwander et al.30, the model may also be regarded
as a special case of Pocock’s bias model, or the model underlying the commensurate
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prior. In both instances, for the case of k = 2 studies, the discrepancy between the
two underlying parameters (here: ϑ1 and ϑ2) is also modeled via a variance parameter
analogous to β2 above. The connection is made somewhat differently in the power
prior model31, where the external data are downweighted via an exponential parameter
between 0 and 1 that is applied to part of the likelihood function. For a given τ (or β)
value, the approaches are again identical when the exponential parameter is set to be(
2 τ
2
σ2
2
+ 1
)−1
or
(
β2
σ2
2
+ 1
)−1
.
Dependency of the shrinkage estimate on the observed
heterogeneity
In the following, we investigate the effect of varying the input data on the resulting
shrinkage estimates. The setup is similar to the one also adopted in the subsequent
simulation study; we consider the case of two estimates (y1 and y2) with standard errors
σ1 = 0.8 and σ2 = 0.2, and we assume a uniform prior for µ and a half-normal (HN)
prior with scale 0.5 for the heterogeneity τ . We set y1 = 0 and then vary the difference
between the estimates (y2 − y1), which is in a sense also the “observed heterogeneity” in
the data. Then we derive the shrinkage estimate for the first parameter θ1.
Figure 1 (top panel) illustrates the effect on the shrinkage estimate and the
corresponding 95% credible interval. One can see how the estimate (posterior median
of θ1) moves (mostly) in concordancewith the second estimate (y2) and that the resulting
interval is narrowest when y1 and y2 are in close agreement. For larger differences, the
estimated heterogeneity increases, less borrowing of information takes place, the interval
widens and the estimate of θ1 is less attracted towards y2. Eventually the shrinkage
interval exhibits a certain degree of robustness and barely changes with increasing
difference. This robustness feature may be explained by the fact that implicitly the meta-
analysis is equivalent to an analysis of the first study using the MAP-prior based on the
second study11. The prior derived via the hierarchical model from the first study then is
rather vague and heavy-tailed, leading to the robust behaviour32.
The middle panel shows that the shrinkage interval is shorter than the “plain” interval
(y1 ± 1.96σ1) when the estimates y1 and y2 are similar, that it may also get wider in some
cases, but that its width eventually is bounded. The bottom panel shows the probability
distribution of the difference y2 − y1 (which has variance σ21 + σ22 + 2τ2) for several
selected values of τ . Based on the assumptions, the absolute difference is unlikely to
exceed a value of, say, |y2 − y1| = 4, and so the probable cases essentially are those in
the left half of the plot.
The scenario shown here is where we would in fact expect the greatest gain from
considering the second estimate (y2) in estimating θ1, since the second estimate’s error is
much smaller than the first (σ2 ≪ σ1). The figure looks qualitatively similar if we match
or reverse the relative magnitudes of the standard errors σ1 and σ2, and also if we use a
wider heterogeneity prior, but in those cases there is less information to be borrowed and
hence less “shrinkage” taking place.
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Figure 1. Effect of varying the difference between quoted estimates (y2 − y1) on the first
shrinkage estimate (for θ1). In the top row, one can see how the interval itself varies relative to
the “plain” interval (y1 ± 1.96σ1, red lines); the second estimate (y2) and its corresponding CI
are shown in green. The second row shows the ratio of interval lengths, and the bottom row
shows the probability density of the actualized difference for selected values of τ . The
heterogeneity prior used here for the analysis was half-normal (HN) with scale 0.5.
Simulation study
Setup
The simulations shown in the following are based on the NNHM, and since binary
endpoints are very common in meta-analysis applications33, the setup is motivated by
a scenario featuring a log-OR endpoint. If a study of size ni results in a contingency
table as an outcome, this may be converted into a log-OR that is associated with an
approximate standard error of σi =
4√
ni
21. A similar formula applies e.g. for logarithmic
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hazard ratios (log-HRs) from a survival analysis with respect to the event counts22. In the
following we will consider combinations of “small”, “medium” and “large” studies of
sizes ni ∈ {25, 100, 400}, corresponding to standard errors of σi ∈ {0.8, 0.4, 0.2}. The
true mean effect µ is (arbitrarily) fixed at zero. Analysis of a pair of studies will be based
on a uniform prior for the effect µ, and a half-normal (HN) prior for the heterogeneity τ .
Heterogeneity values in the range 0.5–1.0may be considered as fairly high and above 1.0
as fairly extreme22. A prior scale parameter of 0.5 already is a conservative choice, but
in addition we also investigate the use of a HN(1.0) prior20,22. The true heterogeneity
values in the simulation will be varied among τ ∈ {0.0, 0.1, 0.2, 0.5, 1.0, 2.0} in order
to check performance conditional on particular τ values. Similarly, we investigate the
marginal performance by drawing τ according to the specified prior distribution. The
primary interest will be in the first of the two studies (i=1) and especially the shrinkage
estimate of its study-specific effect θ1. The number of simulations for each scenario is
10 000.
We can compare the resulting precision by comparing the 95% shrinkage interval
width δi with the original confidence interval width and considering the relative width
qi =
δi
2×1.96σi . Assuming that standard errors scale with n
−0.5
i , we can then estimate
the approximate gain in effective sample size as q−2i − 1. For example, if the shrinkage
interval is only half as wide as the original interval, this precision gain corresponds to
a roughly four-fold (300%) increase in sample size. If the interval is qi=90% as wide,
then this corresponds to an approximate q−2i − 1 = 23% increase. R code to reproduce
the simulations is included in the supplement.
Coverage
Table 1 illustrates the coverage of shrinkage intervals for the effect θ1 for different
combinations of study sizes (n1, n2), heterogeneity values (τ ) and heterogeneity priors
(scales 0.5 and 1.0). The columns marked by an asterisk (∗) correspond to the “marginal”
simulations in which heterogeneity τ is not fixed, but varied according to the specified
prior distribution. Coverages are close to or above the nominal 95% level, except if
heterogeneity approaches a priori improbable large values. For the simulations in which
τ is drawn from its prior distribution, we know that by definition the coverage would
be exactly 95% if the effect µ was also drawn from its prior34. Since the effect prior
is improper and µ was arbitrarily fixed at zero for the simulations, this only holds
approximately here.
Interval length and effective sample size gain
Table 2 shows the mean lengths of shrinkage intervals relative to the original (“plain”)
confidence interval based on y1 and σ1 alone (which has width 2×1.96σ1). While we
have seen in the previous section that intervals may be shorter or longer in certain cases,
here we see that on average the shrinkage intervals are always shorter than the plain
intervals. As expected, the gain is largest if the study under consideration is small relative
to the additional evidence (n1 < n2, σ1 > σ2), and if heterogeneity is low. Assuming a
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10 Journal Title XX(X)
Table 1. Coverage (%) of shrinkage intervals for estimation of the first study’s mean
parameter (θ1). Sample sizes (n1 and n2) as well as settings for the heterogeneity
prior (p(τ )) and actual heterogeneity values (τ ) are varied. The columns labelled by an
asterisk (∗) correspond to drawing the heterogeneity from its corresponding prior distribution.
τ prior: HN(0.5) HN(1.0)
n1/n2 τ : 0.0 0.1 0.2 0.5 1.0 2.0 ∗ 0.0 0.1 0.2 0.5 1.0 2.0 ∗
25/400 99.7 99.6 98.9 93.4 84.0 79.0 94.7 99.3 99.3 99.0 96.7 92.5 90.5 95.1
25/100 98.7 98.7 98.1 93.9 86.1 80.0 95.1 98.4 98.6 98.5 96.5 93.2 90.8 94.4
100/400 98.7 98.2 97.1 93.2 90.9 90.4 94.9 98.1 97.7 97.2 94.8 93.7 93.5 95.3
25/25 96.6 96.7 96.1 94.5 90.5 84.6 95.0 97.0 97.2 96.6 95.7 94.0 92.1 94.9
100/100 96.7 96.5 96.3 94.0 91.1 90.7 95.7 96.7 96.4 96.6 95.3 93.7 93.6 94.9
400/400 96.7 96.6 95.0 94.0 94.0 93.9 95.0 96.4 96.4 95.0 94.9 94.9 94.8 95.0
100/25 96.0 95.6 95.3 94.8 93.8 92.3 94.7 96.0 95.8 95.6 95.2 94.7 94.3 94.8
400/100 95.5 95.6 95.4 94.7 93.7 93.8 95.1 95.6 95.5 95.5 94.9 94.3 94.5 95.1
400/25 95.1 95.1 95.2 94.7 94.9 94.5 95.3 95.0 95.2 95.2 94.8 95.0 95.0 95.2
wider heterogeneity prior also reduces the amount of borrowing of information and leads
to wider intervals.
Table 2. Mean width (%) of shrinkage intervals (for θ1) relative to original “plain” CI based
only on y1 and σ1.
τ prior: HN(0.5) HN(1.0)
n1/n2 τ : 0.0 0.1 0.2 0.5 1.0 2.0 ∗ 0.0 0.1 0.2 0.5 1.0 2.0 ∗
25/400 62.4 62.7 63.0 65.6 72.1 82.9 65.1 75.6 75.9 76.2 78.6 83.8 90.8 81.5
25/100 67.5 67.5 67.9 69.9 75.2 84.3 69.5 78.4 78.4 78.8 80.9 85.2 91.4 83.2
100/400 78.5 78.7 79.9 85.2 91.3 95.8 83.4 85.7 85.8 86.8 90.9 95.0 97.7 92.1
25/25 78.9 79.0 79.0 79.7 81.8 86.9 79.7 85.2 85.2 85.3 86.2 88.4 92.4 87.6
100/100 85.1 85.3 85.7 88.4 92.5 96.2 87.5 89.9 90.1 90.4 92.7 95.6 97.9 93.9
400/400 89.9 90.5 91.9 95.5 97.8 99.0 93.7 93.0 93.4 94.5 97.2 98.7 99.5 97.3
100/25 92.9 92.9 93.0 93.4 94.6 96.6 93.3 95.0 95.0 95.1 95.6 96.7 98.1 96.1
400/100 95.0 95.1 95.4 96.6 98.1 99.1 96.2 96.5 96.6 96.9 97.9 98.9 99.5 98.2
400/25 98.0 98.0 98.1 98.2 98.6 99.2 98.2 98.6 98.6 98.6 98.8 99.1 99.5 99.0
The gain in precision may approximately be translated to an equivalent gain in
effective sample size (as expressed through the qi introduced above). The average gain
is shown in Table 3. This relative gain in information may be substantial and is most
pronounced if n1 is small relative to n2. For example, for the HN(0.5) heterogeneity
prior and n1 = 25, we can expect a gain of at least one third across all scenarios, and
even a gain of more than 100% is well achievable in certain cases. When averaging over
the heterogeneity prior, i.e., if we assume the prior to accurately reflect the probability
distribution for τ , we can expect a gain of more than 50% for the cases where n1 = 25
and more than 100% when in addition n2 > n1.
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Table 3. Gain (%) in effective sample size when using the shrinkage estimate, relative to the
original CI.
τ prior: HN(0.5) HN(1.0)
n1/n2 τ : 0.0 0.1 0.2 0.5 1.0 2.0 ∗ 0.0 0.1 0.2 0.5 1.0 2.0 ∗
25/400 162.7 160.7 158.9 144.3 113.4 68.8 147.9 77.7 76.5 75.4 67.1 50.5 28.9 58.3
25/100 123.3 123.3 121.3 111.3 89.7 56.2 113.8 64.9 64.9 63.6 56.9 43.6 25.5 50.0
100/400 64.6 64.1 60.1 43.7 25.9 12.8 49.4 37.5 37.2 34.4 23.8 13.4 6.3 20.7
25/25 61.2 60.9 60.8 58.4 51.8 36.9 58.7 38.7 38.5 38.2 35.8 30.0 19.6 32.2
100/100 38.8 38.2 37.1 29.8 19.4 10.0 32.3 24.4 23.8 23.0 17.5 10.7 5.3 14.8
400/400 24.3 22.8 19.5 10.9 5.3 2.5 15.1 16.1 15.0 12.5 6.5 3.0 1.3 6.3
100/25 15.9 16.0 15.8 14.8 11.9 7.6 14.9 10.9 10.9 10.7 9.6 7.2 4.2 8.4
400/100 10.9 10.7 10.0 7.3 4.2 2.0 8.3 7.4 7.2 6.6 4.5 2.5 1.1 3.9
400/25 4.1 4.1 4.0 3.7 2.9 1.7 3.7 2.9 2.8 2.8 2.4 1.8 1.0 2.1
Fraction of shortened intervals
While there is a gain on average, the shrinkage intervals may in some cases also turn
out wider than the original interval. Table 4 shows the percentages of intervals showing
a smaller width. In a majority of cases, we can expect a shorter interval, the exceptions
are again cases where the heterogeneity is large, or the second study is small.
Table 4. Fraction (%) of shrinkage intervals turning out shorter than the original CI. Note the
differing ordering of rows compared to Tables 1–3.
τ prior: HN(0.5) HN(1.0)
n1/n2 τ : 0.0 0.1 0.2 0.5 1.0 2.0 ∗ 0.0 0.1 0.2 0.5 1.0 2.0 ∗
25/25 100.0 99.9 100.0 99.7 97.4 81.6 99.5 99.4 99.2 99.1 97.8 91.1 68.6 91.4
25/100 99.9 99.9 99.9 99.1 92.3 68.7 98.6 99.2 99.2 98.8 96.1 83.9 57.6 86.9
25/400 99.9 99.9 99.9 98.9 90.7 64.5 98.1 99.3 99.3 99.1 95.8 82.1 54.4 85.8
100/25 99.8 99.8 99.7 98.6 90.0 65.7 98.1 98.3 98.2 97.9 94.5 80.4 54.1 85.2
100/100 99.4 99.0 98.5 91.0 68.8 39.6 91.5 97.6 96.8 95.5 83.8 59.8 33.4 71.3
100/400 99.1 98.7 97.4 84.2 57.0 31.4 87.2 97.4 96.9 94.5 77.0 50.1 27.0 65.4
400/25 99.7 99.8 99.5 97.6 86.9 59.3 96.9 98.1 98.1 97.0 92.8 76.2 48.8 82.3
400/100 98.6 98.1 95.8 80.6 54.4 29.2 84.7 96.1 95.0 91.2 72.8 46.9 24.5 62.3
400/400 97.6 95.6 88.5 60.1 33.7 17.7 72.0 95.0 92.1 83.2 54.1 30.0 15.5 48.6
Implications for practical application
The previous sections illustrate the process of shrinkage estimation within the NNHM
framework and investigate the potential benefits. Across a range of realistic settings, the
method exhibits sensible and robust behaviour, and despite the seemingly pathological
outset of synthesizing only two estimates, the expected information gain may still be
substantial. In the following, we will illustrate the approach by applying it in two
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examplary cases, onc based on two studies (one randomized, one observational), and
one based on two estimates from meta-analyses of different types of studies.
An application in Creutzfeld-Jakob disease
With a prevalence of 1 in 1 000 00035 and an incidence of 1.5 per million and year36,
Creutzfeld-Jakob disease (CJD) is clearly a rare disease by any standard. In a recent
systematic review, Unkel et al.37 identified a number shortcomings in the methodologies
applied in clinical studies conducted in CJD and advocated the use of innovative
statistical methodology including evidence synthesis approaches.
Varges et al.3 studied the use of doxycycline, an antiprion agent, in early CJD.
They conducted a double-blind randomised placebo-controlled trial that failed to recruit
the originally planned number of patients and was terminated prematurely with only
n = 12 patients (7 on doxycycline and 5 on placebo). Additionally, data were available
from an observational study of n = 88 patients including 55 patients who received
doxycycline. The primary endpoint was all-cause mortality which was analyzed using
Cox proportional hazard regressions. In the case of the randomized controlled trial the
model included only the factor treatment as independent variable whereas the analysis
of the observational data in addition was stratified by propensity scores. The observed
log hazard ratios (standard errors) were −0.173 (0.631) and −0.499 (0.249) in the
randomized controlled trial and the observational study, respectively. Varges et al.
performed a random-effects meta-analysis to estimate the overall (pooled) effect µ using
standard frequentist methodology. They reported a combined hazard ratio of 0.633 with
95% confidence interval of (0.402; 0.999).
Now suppose primary interest was in the ‘randomized’ effect, but one is willing to
utilize external observational evidence as supporting information.We may now apply the
shrinkage estimation approach. Figure 2 shows the estimated logarithmic hazard ratios
based on obervational and randomized data along with the derived mean estimate (µ).
The two shrinkage estimates are also shown next to the original (quoted) estimates. For
the randomized trial, the updated credible interval covers the range of [−1.16, 0.48] and
is only 66% as wide as the original interval. This amount of shrinkage implies a gain
in effective sample size of 129%, i.e., this corresponds to more than a doubling of the
original sample size from 12 patients to an ‘effective number’ of some 27 patients. For
the randomized patients’ shrinkage estimate, we then obtain a posterior probability of
a non-beneficial effect of P(θrand.>0 | y) = 0.16. The associated (one-sided) posterior
predictive p-value is similar, with p = 0.13.
From two studies there is only very little to be learned about the between-study
heterogeneity τ 24. The prior median heterogeneity was at 0.34, which a posteriori is
slightly reduced to 0.28; the posterior 95% quantile is at 0.85 instead of 0.98. Note that
while the estimates for the overall mean and the shrinkage estimate do not differ much in
this particular case, their interpretations are quite different. The R code to reproduce the
calculations for this example is provided in the appendix.
Prepared using sagej.cls
Ro¨ver & Friede 13
quoted estimate shrinkage estimate
study
observational
randomized
mean
patients
88
12
estimate
−0.50
−0.17
−0.43
95% CI
[−0.99, −0.01]
[−1.41, 1.06]
[−1.23, 0.42]
−1.5 −1 −0.5 0 0.5 1
log−HR
Figure 2. Forest plot for the CJD example (log-HR outcome). The shrinkage interval for the
log-HR based on randomized evidence here is [−1.16, 0.48], spanning only two thirds of the
original confidence interval width.
Beyond two studies: more general shrinkage applications
So far we have described shrinkage estimation mostly in terms of “studies” and
corresponding parameter estimates. However, the method may be applied more widely.
Estimates do not need to come from studies, these could also originate from different
types of evidence, for example, from two meta-analyses, or from a meta-analysis and a
single study.
If the NNHM is fitted to the results of meta-analyses, then this adds another
hierarchical level to the model. In the spirit of a bias allowance model framework38,
in addition to between-study variability, the variability between study types is considered
as a separate variance component. Especially in the context of normal models39,40 and
when interest is in main effects41, application of a one-stage model simultaneously
including all hierarchy levels may in many cases not lead to substantially different results
from a simpler two-stage approach in which data at the study-level are combined first,
and summaries are subsequently combined in a second stage42. This way, inference is
substantially simplified, and standard meta-analysis software can be used.
Consider the example of a meta-analysis investigating the effect of immunosuppres-
sion in paediatric patients, where the outcome of interest is the occurrence of acute
rejection (AR) events that the therapy is supposed to prevent43. Only two randomized
trials are available, but in addition four observational studies reported on the effect. One
may not expect to see identical effects in both types of studies, but the discrepancy
between them will be limited. A meta-analysis of the two randomized trials may then
profit from considering the outcomes of the four observational trials in addition, leading
to a particular kind of extrapolation approach44.
Figure 3 shows the example data. In both sets of studies we see similar effects,
the negative combined estimates of the log-odds-ratio indicate a successful prevention
of AR events, and the two associated credible intervals are mostly overlapping. After
combining the two sets of studies separately, we may now perform a meta-analysis
of the resulting two combined estimates (in all cases using uniform priors for effects
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observational
randomized
study
Gibelli (2004)
Schuller (2005)
Ganschow (2005)
Gras (2008)
   observational combined
Heffron (2003)
Spada (2006)
   randomized combined
   randomized shrinkage
control
19 / 28
 8 / 12
29 / 54
 3 / 34
15 / 20
11 / 36
treatment
16 / 28
 3 / 18
 9 / 54
 0 / 50
14 / 61
 4 / 36
log−OR
−0.460
−2.303
−1.758
−2.418
−1.467
−2.310
−1.258
−1.810
−1.659
s.e.
0.556
0.880
0.456
1.529
0.434
0.599
0.642
0.556
0.419
95% CI
[−1.550, 0.631]
[−4.028, −0.577]
[−2.651, −0.864]
[−5.414, 0.579]
[−2.336, −0.611]
[−3.485, −1.135]
[−2.517, −0.000]
[−2.910, −0.708]
[−2.494, −0.838]
−4 −3 −2 −1 0 1
logarithmic OR
Figure 3. Illustration of a more general shrinkage application. The two sources of evidence
themselves here are meta-analyses of observational and randomized studies. The combined
randomized estimate may then borrow information from the observational studies’ evidence.
The two combined estimates are again meta-analysed to yield a shrinkage interval for the
randomized effect.
and HN(0.5) priors for heterogeneities). The shrinkage estimate for the mean effect in
the randomized studies then provides an estimate for the randomized effect that is also
informed by the observational evidence, while allowing for heterogeneity (at a second
level) between both types of estimates. Note that in this context the shrinkage estimate
then does not refer to a single study, but to one of the meta-analysis estimates that
are combined here. The shrinkage estimate is shown at the very bottom of Figure 3.
Compared to the original estimate based only on the two randomized trials, the shrinkage
estimate is, in concordance with the observational evidence, slightly more moderate (at
a lower absolute log-OR). Consideration of the additional evidence also gains precision:
the shrinkage interval is 25% shorter than the original interval.
For the shrinkage estimate, we get a posterior probability of P(θrand.>0 | y) =
0.00007 of a non-beneficial effect. With p = 0.0002, the associated posterior predictive
p-value again is of a similar magnitude. Compared to the original meta-analysis of
2 randomized studies only, we can again see the gain in precision; here the evidence
for a beneficial effect was not yet quite as pronounced (P(µ>0 | y) = 0.0023 and
p = 0.0079). The R code to reproduce the calculations for this example is provided in
the appendix.
Discussion
Use of the NNHM to consider external information via shrinkage estimation provides
a transparent procedure based on well-defined parameters and a common model
framework. The NNHM may readily be generalized e.g. to more studies, more levels
of hierarchy, or the inclusion of regression parameters. The amount of information
considered may be explicated by noting that a joint analysis is equivalent to the use
of a meta-analytic-predictive (MAP) prior11. At the same time, heavy tails of the MAP
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prior ensure a certain degree of robustness of the shrinkage estimate in case of prior-
data conflicts32. The simulations demonstrate that the gain in precision may be greater
than expected, and substantial especially in cases where the external data are associated
with equal or less uncertainty than the data that are of primary interest. The possible
precision gain may allow the conduct and evaluation of trials in circumstances where
otherwise evidence would be too sparse, or it may generally enable to allocate resources
more efficiently.
In the spirit of the reference model parametrization outlined above, the institution of
an “overall mean” µ is not necessary. In many cases, when the data to be synthesized are
of differing natures, the idea of a “central” mean parameter might be hard to motivate;
what is relevant here is that the two estimates are modeled as being connected via
an uncertain normally distributed offset. Normality here especially implies symmetry,
i.e., the displacement between the two does not have a preferred direction; over- or
under-estimation of one another are equally likely, so that a priori no systematic bias
is assumed. Availability of this alternative motivation broadens the range of applicability
of meta-analytic methods.
As usual, the user needs to be aware of the limits of the applicability of the model,
which here in particular means that the normality assumptions should be plausible45.
These assumptions might be challenged e.g. when estimates are based on count data
suffering from small-sample or rare-event problems, in which case more specific
models may be more appropriate46. We also make the implicit assumption that patient
populations are sufficiently similar to allow for a meaningful comparison. Furthermore,
analyses of non-randomized studies may need to be adjusted for confounding47,48, as was
also done in the CJD example.
Although frequentist analyses still dominate clinical trials, examples of Bayesian
analyses are emerging. A recent application is the trial by Laptook et al.49 in newborns
with hypoxic-ischemic encephalopathy, a form of brain damage resulting from an
insufficient supply of oxygen to the brain. The authors used the Bayesian framework to
interpret their results in the light of different choices of priors that they termed “neutral”,
“skeptical” and “optimistic”50. In this regard it differs from our proposal as we advocate
the use of external data to inform the prior. The connection to common meta-analysis
methods then helps motivating the choice of model details. Sensitivity analyses could be
performed in our setting by varying the prior on the between-trial heterogeneity τ , e.g.
by varying the scale parameter of the half-normal prior.
Although not assessed in the simulations here, the performance of frequentist
shrinkage BLUP estimators is likely to be unsatisfactory when dealing with only two
studies. The reason lies in the underestimation of the between-study heterogeneity with a
high likelihood of the variance estimate resulting in zero, and the challenge to incorporate
the uncertaintly in the estimation of the heterogeneity in the inference20,24,51. A Bayesian
alternative was described here and shown in simulations to have satisfactory properties
under practically relevant scenarios. Therefore, the approach described here adds to
the tool box of practicing statisticians. The proposed Bayesian approach can easily be
implemented using the R package bayesmeta21,26 and relevant code is provided as
appendices for the two-study and the two-meta-analyses cases. The code to reproduce
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the simulations is also provided in the online supplement. The availability of posterior
predictive p-values may aid in the interpretation of the findings. Furthermore, the
efficient implementation facilitates sensitivity analyses and the assessment of operation
characteristics of the procedures through simulations in so-called clinical scenario
evaluations52.
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Appendix
R code for CJD example
# specify the data:
cjd <- cbind.data.frame("study" = c("observational", "randomized"),
"logHR" = c(-0.49948, -0.17344),
"logHR.se" = c(0.2493, 0.6312),
stringsAsFactors=FALSE)
# analyze:
require("bayesmeta")
bm <- bayesmeta(y = cjd$logHR,
sigma = cjd$logHR.se,
labels = cjd$study,
tau.prior = function(t){dhalfnormal(t, scale=0.5)})
# show results:
bm
forestplot(bm)
# show shrinkage estimates:
bm$theta
# interval length ratio (66%):
(q <- diff(bm$theta[7:8,"randomized"])
/ (2*qnorm(0.975)*bm$theta[2,"randomized"]))
# effective sample size gain (129%):
(1/q)ˆ2 - 1
# heterogeneity prior median and 95% quantile:
qhalfnormal(c(0.50, 0.95), scale=0.5)
# heterogeneity posterior:
bm$summary[,"tau"]
# compute posterior predictive p-value
# (one-sided, for the randomized (shrinkage) effect,
# and using the posterior probability of a beneficial effect
# as the "test statistic"):
p1 <- pppvalue(bm, parameter="randomized", value=0,
alternative="less", statistic="cdf",
n=1000, seed=123)
p1
# for comparison, the posterior probability
# of a non-beneficial randomized effect:
1 - bm$pposterior(theta=0, individual="randomized")
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R code for paediatric transplantation example
# load packages and data:
require("bayesmeta")
data("CrinsEtAl2014")
# compute effect sizes (log-OR for acute rejection (AR) events)
# using the metafor library’s "escalc()" function;
# 4 observational studies:
effsize.obs <- escalc(ai = exp.AR.events, n1i = exp.total,
ci = cont.AR.events, n2i = cont.total,
slab = publication, measure = "OR",
subset = (CrinsEtAl2014[,"randomized"]=="no"),
data = CrinsEtAl2014)
# 2 randomized studies:
effsize.rand <- escalc(ai = exp.AR.events, n1i = exp.total,
ci = cont.AR.events, n2i = cont.total,
slab = publication, measure = "OR",
subset = (CrinsEtAl2014[,"randomized"]=="yes"),
data = CrinsEtAl2014)
# perform meta-analysis of 4 observational studies:
bm.obs <- bayesmeta(effsize.obs,
tau.prior = function(x){dhalfnormal(x,scale=0.5)})
# perform meta-analysis of 2 randomized studies:
bm.rand <- bayesmeta(effsize.rand,
tau.prior = function(x){dhalfnormal(x,scale=0.5)})
# perform 2nd-stage meta-analysis of previous MA results:
bm.combi <- bayesmeta(y = c(bm.obs$summary["mean","mu"],
bm.rand$summary["mean","mu"]),
sigma = c(bm.obs$summary["sd","mu"],
bm.rand$summary["sd","mu"]),
labels = c("observational", "randomized"),
tau.prior = function(x){dhalfnormal(x,scale=0.5)})
# compare "plain" randomized posterior and shrinkage estimate:
rbind("randomized-only" = bm.rand$summary[,"mu"],
"shrinkage" = bm.combi$theta[-(1:2),"randomized"])
# interval length ratio (75%):
(q <- diff(bm.combi$theta[7:8,"randomized"])
/ diff(bm.rand$summary[5:6,"mu"]))
# compute posterior predictive p-value:
p1 <- pppvalue(bm.combi, parameter="randomized", value=0,
alternative="less", statistic="cdf",
n=1000, seed=123)
p1
# posterior probability of a non-beneficial randomized effect:
1 - bm.combi$pposterior(theta=0, individual="randomized")
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# compute posterior predictive p-value
# for initial MA of 2 randomized studies only:
p2 <- pppvalue(bm.rand, parameter="mu", value=0,
alternative="less", statistic="cdf",
n=1000, seed=123)
p2
# original posterior probability of non-beneficial effect:
1 - bm.rand$pposterior(mu=0)
Model equivalence
Shrinkage estimation in the NNHM and in the reference model introduced above yield
identical results, as long as an improper uniform prior for the effect (µ or α) is used.
The heterogeneity prior densities are given by p⋆(τ) for then NNHM, and by
1√
2
p⋆
(
β√
2
)
for the reference model. Equivalence of the two models for the shrinkage estimates can
be seen by comparing the resulting MAP priors p(θ2|y1) and p(ϑ2|y1). To do so, we
first introduce a reparametrisation (re-scaling) of the heterogeneity parameter as γ = β√
2
,
where the new heterogeneity parameter’s prior distribution then simply is given by p⋆(γ).
The corresponding MAP prior densities then are given by
p(θ2|y1) =
∫ ∫
p(θ2|µ, τ) p(µ, τ |y1) dµ dτ (7)
∝
∫ [∫
p(θ2|µ, τ) p(y1|µ, τ) dµ
]
p⋆(τ) dτ (8)
and
p(ϑ2|y1) =
∫ ∫
p(ϑ2|α, γ) p(α, γ|y1) dα dγ (9)
∝
∫ [∫
p(ϑ2|α, γ) p(y1|α, γ) dα
]
p⋆(γ) dγ (10)
In order to show that the integrals are identical, it now suffices to show that the terms in
square brackets (the “conditional MAP priors” p(θ2|y1, τ) and p(ϑ2|y1, γ), respectively)
are identical. For the NNHM we have
∫
p(θ2|µ, τ) p(y1|µ, τ) dµ
=
∫
1√
2πτ2
exp
(
− 12 (θ2−µ)
2
τ2
)
1√
2π(τ2+σ2
1
)
exp
(
− 12 (y1−µ)
2
τ2+σ2
1
)
dµ (11)
= 1√
2π(2τ2+σ2
1
)
exp
(
− 12 (θ2−y1)
2
2τ2+σ2
1
)
(12)
Prepared using sagej.cls
20 Journal Title XX(X)
where the integral results as a convolution of two normal densities. Analogously, for the
second variation we get
∫
p(ϑ2|α, γ) p(y1|α, γ) dα
=
∫
1√
2π 2γ2
exp
(
− 12 (α−ϑ2)
2
2γ2
)
1√
2πσ2
1
exp
(
− 12 (α−y1)
2
σ2
1
)
dα (13)
= 1√
2π(2γ2+σ2
1
)
exp
(
− 12 (ϑ2−y1)
2
2γ2+σ2
1
)
(14)
With that, the two resulting MAP priors are identical, and the two models will yield the
same results as far as the shrinkage estimates are concerned.
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